Expression Changes in the Stroma of Prostate Cancer Predict Subsequent Relapse

Biomarkers are needed to address overtreatment that occurs for the majority of prostate cancer patients that would not die of the disease but receive radical treatment. A possible barrier to biomarker discovery may be the polyclonal/multifocal nature of prostate tumors as well as cell-type heterogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Zhenyu, Rahmatpanah, Farah B., Chen, Xin, Lernhardt, Waldemar, Wang, Yipeng, Xia, Xiao-Qin, Sawyers, Anne, Sutton, Manuel, McClelland, Michael, Mercola, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411675/
https://www.ncbi.nlm.nih.gov/pubmed/22870216
http://dx.doi.org/10.1371/journal.pone.0041371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411675/
https://www.ncbi.nlm.nih.gov/pubmed/22870216
http://dx.doi.org/10.1371/journal.pone.0041371

Ejemplares similares